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Abstract RNA ligands were generated against various gene
products present in HeLa nuclear extract. Functional profiling
was performed to identify RNA ligands that modulate RNA
polymerase II (pol II)-mediated transcription. Unexpectedly,
four of the eight inhibitor ligands identified by this screen
contained an 11-nucleotide sequence identical to the 5P-splice
site of eukaryotic pre-mRNAs. Such ligands were shown to
impede pre-initiation complex assembly on a cytomegalovirus
promoter. In addition, U1 small nuclear ribonucleoprotein
particles (snRNP) and pol II had been co-immunoprecipitated
in the absence of transcription. These results suggest a role
for U1 snRNP in co-ordinating transcription and RNA
splicing. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In eukaryotes, nearly all pre-mRNAs are exclusively tran-
scribed by RNA polymerase II (pol II) and undergo splicing
and other processing events to become templates for protein
synthesis. The initiation of transcription by pol II, which rep-
resents a key step for the regulation of gene expression, in-
volves numerous basal transcription factors and diverse trans-
acting regulators [1]. Increasing evidence has indicated that
the transcription and processing of pre-mRNA are co-ordi-
nated events in the nucleus. Pol II appears to interact with a
variety of RNA processing factors and to mediate RNA pro-
cessing co-transcriptionally [2^14]. In these studies, however,
RNA processing factors have been perceived to act restric-
tively ‘downstream’ of transcription initiation even though
they are found in close proximity with the transcription ma-
chinery [15,16].
Recently, it has been established that an iterated enrichment
process (systematic evolution of ligands by exponential enrich-
ment, SELEX) from libraries of random nucleic acid mole-
cules can generate RNA or DNA ligands with high a⁄nity
and speci¢city for various targets [17^19]. This present study
shows that small RNA molecules (RNA ligands) isolated
from a combinatorial selection abolish transcription initiation
from a pol II promoter through interaction with U1 small
nuclear ribonucleoprotein particles (snRNP) and that pol II
and U1 snRNP associate in the absence of transcription.
These results yield new insights into the connection between
transcription and RNA processing in that U1 snRNP is in-
volved in the co-ordination of these events.
2. Materials and methods
2.1. Selection
The initial pool of DNA templates for RNA molecules was con-
structed by annealing two chemically synthesized overlapping DNA
oligos: template oligo containing a section of 40 random nucleotides
(nt) and constant £anking sequences on either side (template oligo, 5P-
GAGGAAGAGGGATGGGN40CATAACCCAGAGGTCGAT-3P),
and complementary 5P-DNA oligo (5P-PR, GGGGGAATTCTA-
ATACGACTCACTATAGGGAGAGAGGAAGAGGGATGGG),
which were converted into double-stranded (ds) DNA by DNA poly-
merase I (Promega). In later rounds, the DNA templates were regen-
erated from RNA molecules by reverse transcriptase (Roche) and
polymerase chain reaction (PCR) with primers 5P-PR and 3P-PR
(GGGGGGATCCAGTACTATCGACCTCTGGGTTATG). The
RNA molecules were synthesized by T7 RNA polymerase (Roche)
in vitro and puri¢ed on a 10% polyacrylamide/7 M urea gel after
the DNA templates were removed by DNase I digestion (Promega),
and quantitated with a UV spectrometer (Beckman). In other experi-
ments, RNA molecules (RNA 9A, 9B and 9C) with mutated sequen-
ces of a selected ligand (RNA 9) were generated by T7 RNA poly-
merase with the same methods from dsDNA templates obtained
through PCR with primers 5’PR and 3’PR and synthetic DNA oligos
(RNA 9A, 5P-GAGGAAGAGGGATGGGAGTCCACGAGCGT-
ATCCAGTATCCACAGACATAACCCAGAGGTCGAT-3P ; RNA
9B, 5P-GAGGAAGAGGGATGGGGTAGGTAAGTACAATCCA-
GTATCCACAGACATAACCCAGAGGTCGAT-3P ; RNA 9C, 5P-
GAGGAAGAGGGATGGGAGTCCACGAGCGTAGGTAAGTA-
CAATAGACATAACCCAGAGGTCGAT-3P, respectively). In the
¢rst round, HeLa nuclear extract (200 Wg) and RNA (10 nmol, tran-
scribed from dsDNA templates of around 6U1014 di¡erent sequences)
were combined in a volume of 1 ml of incubation bu¡er (20 mM
HEPES, pH 7.9; 100 mM KCI; 0.2 mM EDTA; 0.5 mM DTT;
20% glycerol). The HeLa nuclear extract was prepared as previously
described [20]. In later rounds, nuclear proteins (20^25 Wg), and RNA
(V1 nmol) were incubated in a volume of 100 Wl. The unbound RNA
molecules were found to be rapidly degraded in the HeLa nuclear
extract while the bound RNA molecules remain intact. For each of
the ¢rst eight rounds of selection, RNA/protein binding was assayed
with a gel mobility-shift assay in a wide range of protein concentra-
tions and variable time of incubation, and the integrity of RNA
ligands was detected by denaturing gel electrophoresis. Particular pro-
tein concentrations and time of incubation were chosen to remove
90% of the input RNA molecules. From the ninth to fourteenth
rounds, a gel mobility-shift assay was used to isolate the bound
RNA molecules from each pool. The mixture of 32P-labeled RNA,
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HeLa nuclear proteins (25 Wg) and tRNA (20 Wg) was incubated at
37‡C for 30 min and loaded on a 5% non-denaturing polyacrylamide
gel (acrylamide:bis-acrylamide, 80:1). Radiolabeled RNA species that
migrated more slowly than free RNA on the gel were isolated, eluted
from gel by shaking in sodium acetate (0.3 M), extracted by phenol,
precipitated by ethanol and converted into dsDNA template through
reverse transcription (RT)/PCR for the next round of selection. For
RT/PCR, the ¢rst DNA strand was synthesized with RNA molecules
and 3P-PR using a reverse transcription kit (Roche), followed by PCR
with 3P-PR and 5P-PR using a PCR kit (Life Technologies). Through
this selection process, RNA ligands appeared to be generated to a
variety of targets present in the extract as evidenced by the appear-
ance of numerous shifted RNA complexes that appeared in later
rounds of selection (data not shown). For cloning, the dsDNA tem-
plates from the fourteenth round were ligated into pUC19 vector
(New England Biolab) through EcoRI and BamHI restriction sites,
which was used to transform DH5K Escherichia coli competent cells
(Life Technologies). For imaging, gels were either dried for autora-
diography with a Storm 840 Phosphorimager (Molecular Dynamics),
or directly exposed to Fuji X-ray ¢lms that were processed with a
Kodak ¢lm processor.
2.2. Pol II transcription and pre-initiation complex analysis
Various competitor RNAs including tRNA, Pool 1 and 14 RNA,
and RNA ligands (35, 70 and 105 pmol) were added to fresh HeLa
nuclear extract (45Wg; Promega) with RNasin (40 U; Roche) and pre-
incubated at 30‡C for 15 min. BamHI linearized DNA template (200
ng) containing a cytomegalovirus (CMV) promoter and human L-
globin exons 1, 2 and introns, rNTPs (0.4 mM), Mg2 (3 mM) and
[K-32P]GTP (10 WCi, 800 Ci/mmol, Amersham) in 44% transcription
bu¡er (20 mM HEPES, pH 7.9; 100 mM KCl; 0.2 mM EDTA; 0.5
mM DTT; 20% glycerol) were added to initiate transcription in a
total volume of 25 Wl at 30‡C (60 min). An RNA loading control
(V700 nt) generated by T7 in vitro transcription was added to the
pol II transcription reactions just prior to RNA extraction by phenol.
The transcripts were resolved on a 6% polyacrylamide/7 M urea gel.
For post-initiation inhibition of pol II transcription by ligands, the
experimental conditions were as described above except that samples
were pre-incubated in parallel before and after the addition of RNA
ligands. After the globin DNA template and HeLa nuclear extract
were pre-incubated at 30‡C for 30 min, increasing amounts of RNA
9 (35, 70 and 105 pmol) were added to the mixture which was incu-
bated at 30‡C for another 30 min. Transcriptions were started by
adding the rest of the transcription mix, and total RNA was extracted
45 min after transcription initiation.
Pol II binding to the pre-initiation complex was analyzed on an
immobilized dsDNA containing the CMV promoter. The CMV pro-
moter DNA was generated by PCR with an upstream vector-speci¢c
primer (5P-AGTCGTGACGTGAATTACG-3P) and a biotinylated
DNA oligo speci¢c for L-globin exon 2 (5P-biotin-GGATATCGC-
GACTCACCACCAACTTCATCCACGTTC-3P), and immobilized
on streptavidin-coated agarose beads (Pierce). The transcription pre-
initiation complex was assembled on the immobilized CMV promoter
DNA in the presence or absence of HeLa nuclear proteins (45 Wg) and
RNA competitors (105 pmol each). Promoter bound proteins were
eluted with 1Usodium dodecyl sulfate (SDS) loading bu¡er (50 mM
Tris^Cl, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue,
10% glycerol), resolved on a 10% polyacrylamide/SDS gel and trans-
ferred onto a nitrocellulose membrane (SchleicherpSchuell) for West-
ern blot analysis with anti-pol II (N-20, Santa Cruz Biotech).
2.3. Pol III transcription
The in vitro transcriptions by pol III were performed according to
previously described methods [21] with modi¢cations. Brie£y, each
reaction contained BamHI linearized plasmid DNA (200 ng) with a
human U6 RNA gene promoter and an 1170 bp ribozyme construct
at downstream, HeLa nuclear extract (45 Wg), rNTP (0.4 mM each),
RNasin (40 U; Roche), Mg2 (3 mM), [K-32P]GTP (10 WCi, 800 Ci/
mmol, Amersham) and 16 mM creatine phosphate in 44% transcrip-
tion bu¡er (20 mM HEPES, pH 7.9; 100 mM KCl; 0.2 mM EDTA;
0.5 mM DTT; 20% glycerol) in a volume of 25 Wl. The transcriptions
were carried out at 30‡C for 60 min. The e¡ects of RNA ligands (105
pmol each) as well as K-amanitin (1, 50 and 100 Wg/ml, Roche) on pol
III activity, and transcripts were analyzed with the same methods for
pol II as described above.
2.4. Oligonucleotide-directed cleavage by RNase H
Targeted depletion of U1 and U3 RNA sequences by RNase H
cleavage was mediated by a deoxyoligonucleotide (anti-U1, 5P-
TTCAGGTAAGTACTCA-3P) speci¢c for the 5P-terminal U1 RNA
[22] and one (anti-U3, 5P-TGGTTTTCGGTGCTCT-3P) speci¢c for a
putative single-stranded region of U3 RNA [23]. For RNase H cleav-
age reactions, HeLa nuclear extract (45 Wg), RNasin (40 U; Roche),
deoxyoligonucleotides (200 ng), RNase H (1 U, Roche), Mg2 (3
mM) and transcription bu¡er (20 mM HEPES, pH 7.9; 100 mM
KCl; 0.2 mM EDTA; 0.5 mM DTT; 20% glycerol) in a volume of
15 Wl were incubated at 30‡C for 45 min. The snRNA-depleted nu-
clear extract samples were tested for transcription activities as well as
the e¡ect by RNA ligands.
2.5. Immunoprecipitation, RNA a⁄nity chromatography and Western
blot
For immunoprecipitation, 1 Wg of a murine anti-U1 70k antibody
(Santa Cruz Biotech) or IgG (Sigma) was incubated with or without
45 Wg HeLa nuclear extract, and precipitated by 4 Wl of £urry protein
G-Sepharose beads (Pharmacia) in 50 Wl IP bu¡er [24] on a slow
rotating shaker at 4‡C for 4 h. The beads were washed twice with
50 Wl IP bu¡er. For RNA-based a⁄nity chromatography, HeLa nu-
clear proteins were loaded onto columns containing streptavidin^aga-
rose beads without RNA ligands (beads) or tagged with RNA ligands
5 or 9. The ligands were appended to the beads by hybridizing them
to a biotinylated 2P-O-methyl-RNA oligonucleotide (5P-biotin-
AGUACUAUCGACCUCUGGGUUAUG-3P) that is complementa-
ry to part of the ligand’s 3P-constant sequence. After washing, the
bound proteins were eluted with a DNA oligonucleotide (3P-PR) com-
plementary to the entire 3P-constant sequence of the RNA ligands.
Protein samples from the a⁄nity chromatography or immunoprecipi-
tation were boiled in SDS loading bu¡er, resolved on a 10% polyac-
rylamide/SDS gel and electrically transferred onto a nitrocellulose
membrane (SchleicherpSchuell). Western blot analysis was carried
out with an ECL kit (Amersham). The membrane was pre-blocked
with 5% blocking reagent (Amersham) before being probed with a
rabbit anti-pol II monoclonal antibody (N-20, Santa Cruz Biotech)
speci¢c to an N-terminal epitope of the largest subunit of pol II, or
with an anti-U1 70k antibody (Santa Cruz Biotech).
3. Results and discussion
Combinatorial selection of RNA ligands against crude cel-
lular extracts through SELEX provides the possibility of ob-
taining arrays of ligands for numerous cellular targets from
the same selection. These ligands may be used to characterize
the target molecules involved in various activities (e.g. [24]).
To determine if RNA ligands had been generated that could
impede pol II-mediated transcription, the DNA templates for
round 14 (see Section 2) were cloned and RNAs from 60
random clones were screened for their activity in an in vitro
transcription assay. Among the 60 RNA molecules, eight
were found to strongly inhibit pol II transcription from a
CMV promoter. To determine if this inhibition was dose-de-
pendent, the activity of the RNA ligands was analyzed over a
range of concentrations. As shown in Fig. 1A, RNA 9, 13, 15
and 43 strongly repressed transcription in a dose-dependent
manner, while RNA 5 as well as pool 1 RNA and several
others (e.g. RNA 22, 35 and 47, data not shown) showed
only a slight e¡ect on transcription at these concentrations.
Several other ligands (RNA 30, 32, 48 and 58) also showed
similar inhibition (data not shown). Unexpectedly, four of the
inhibitors contain an 11 nt consensus sequence identical to
the 5P-splice site sequence found in eukaryotic pre-mRNAs
(Fig. 1B), while neither the non-inhibitors nor the other in-
hibitors contain this consensus. The transcription inhibition
appeared to be pol II-speci¢c, because these RNA ligands
(RNA 9, 13, 15 and 43, lanes 2^5, Fig. 1C) showed no e¡ect
on the transcription by pol III from a human U6 RNA gene
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promoter at the concentration that pol II had been strongly
inhibited. The activity of pol III was con¢rmed by its insen-
sitivity to low concentrations of K-amanitin (lanes 7^9, Fig.
1C), which is characteristic to the pol III in human and other
organisms [21,25,26].
This study has focused on determining how the RNA li-
gands with the 5P-splice site abrogate pol II transcription. To
determine whether U1 snRNP associates with pol II, U1
snRNP was immunoprecipitated from the HeLa nuclear ex-
tract with a monoclonal antibody raised against the U1 70k
subunit, and the immunoprecipitates were subject to Western
blotting with an antibody speci¢c for pol II. As shown in Fig.
2A, the largest subunit of pol II was detected with the anti-
body (N-20) speci¢c for an epitope at the amino-terminus of
the subunit. In separate experiments, puri¢ed RNA 5 (non-
inhibitor) and RNA 9 (inhibitor) were a⁄xed to the streptav-
idin-crosslinked beads via a biotin linkage and used to purify
proteins recognized by these ligands from HeLa nuclear ex-
tract. U1 snRNP and pol II were co-puri¢ed through the
a⁄nity chromatography using columns tagged with RNA 9,
but not with RNA 5 or beads alone (data not shown). These
results indicate that U1 snRNP associates with pol II in vitro
in the absence of transcription and that the RNA ligands do
not appear to impede this association.
To determine if the 5P-splice site is required for the tran-
scription inhibition by the RNA ligands, several mutated se-
quences of RNA 9 with or without the 5P-splice site were
tested for an e¡ect on pol II transcription. As shown in Fig.
2B, the transcription inhibition was abolished when the 11 nt
5P-splice site sequence was deleted from RNA 9 (RNA 9A,
lanes 2^4), but was not a¡ected when an 11 nt adjacent se-
quence was removed from either side of the 5P-splice site
(RNA 9B, lanes 5^7; RNA 9C, lanes 8^10). Experiments
were also conducted to determine if the 5P-terminal sequence
of U1 RNA, which recognizes the 5P-splice site of pre-
mRNAs, is required for transcription inhibition by RNA 9.
The 5P-terminal sequence of U1 RNA as well as a single-
stranded region of U3 RNA [23] was depleted through oligo-
nucleotide-directed cleavage by RNase H [22]. As shown in
Fig. 2C, depletion of the 5P-terminal sequence of U1 RNA
abolished the transcription inhibition by RNA 9 (lanes 2^4),
while removal of a U3 RNA sequence showed no e¡ect (lanes
5^7) compared to when both U1 and U3 RNAs were intact
(lanes 8^10). These results indicate that the inhibition of pol II
transcription by the RNA ligands containing a 5P-splice site is
mediated through interaction with the pol II-associated U1
snRNP.
To determine the mechanism of transcription inhibition,
RNA 9 was added to transcription reactions prior to and
following pre-initiation complex assembly on the CMV pro-
Fig. 1. Inhibition of in vitro transcription of L-globin sequences
from the CMV promoter by RNA ligands. A: RNA ligands (35, 70
and 105 pmol) were added to HeLa nuclear extract (45 Wg) with
RNasin (40 U) and pre-incubated at 30‡C for 15 min. DNA tem-
plate, rNTPs, Mg2 and 32P-GTP were added to start transcription
in a total volume of 25 Wl at 30‡C for 60 min. Band a, L-globin
transcript (1100 nt) derived from the DNA template with the CMV
promoter; band b, RNA loading control (700 nt) which was gener-
ated by T7 in vitro transcription and added to the CMV transcrip-
tion reactions just prior to RNA extraction for electrophoresis on a
6% polyacrylamide/7 M urea gel. ST, control with no RNA ligands.
B: Sequences of RNA ligands (random region only) isolated from
pool 14. The four inhibitors (RNA 9, 13, 15 and 43) contain an 11
nt consensus sequence at variable positions (underlined), which is
identical to the eukaryotic 5P-splice site. The other four inhibitors
(RNA 30, 32, 48 and 58) do not contain this consensus. Non-inhibi-
tors (RNA 5, 22, 35 and 47) showed very limited e¡ect on pol II
activity. Bottom, comparison of the 5P-end of U1 snRNA and the
consensus of the inhibitor RNAs. 8, pseudouridine; m, methyl
group; Gm3, trimethyl guanosine cap. C: E¡ects of RNA ligands on
pol III activity. RNA ligands (105 pmol each) were added to HeLa
nuclear extract (45 Wg) with RNasin (40 U) and pre-incubated at
30‡C for 15 min. The rest of the transcription mix were added to
start transcription in a total volume of 25 Wl at 30‡C for 60 min.
Band c, a ribozyme transcript (1170 nt) derived from the DNA tem-
plate with a human U6 RNA gene promoter; band b, RNA loading
control (700 nt), from the same batch but twice the amount as used
in Fig. 2B, added before RNA extraction for electrophoresis on a
6% polyacrylamide/7 M urea gel. Lane 1, ST, without RNA li-
gands; lanes 7^9, in the presence of K-amanitin (1, 50 and 100 Wl/
ml, respectively).
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Fig. 2. Interaction of U1 snRNP and pol II. A: Co-immunoprecipi-
tation of pol II and U1 70k from HeLa nuclear extract. A murine
anti-U1 70k antibody (K-U1/70k, 1 Wg) as well as mouse IgG (1 Wg)
was incubated with or without HeLa nuclear extract (45 Wg), and
bound proteins were immunoprecipitated with protein G^Sepharose
beads. Western blot analysis was conducted using an antibody (N-
20) speci¢c to an N-terminal epitope of the largest subunit of pol
II. HeLa NE, straight HeLa nuclear extract; mIgG, mouse immuno-
globulin G. B: E¡ects of RNA molecules with mutated inhibitor
RNA 9 sequences (RNA 9A, 9B and 9C) on pol II transcription.
These RNA molecules either lack (RNA 9A, lanes 2^4) or contain
(RNA 9B and RNA 9C; lanes 5^7 and 8^10, respectively) the 5P-
splice site (underlined). Only sequences in the random region are
shown. The methods are as described in Fig. 1A. ST, control with-
out RNA ligands (lane 1). Band a, L-globin transcript; band b,
loading control RNA. C: E¡ects of targeted depletion of snRNAs
on the ligand-mediated inhibition of pol II transcription. U1- and
U3-speci¢c RNA sequences were depleted by RNase H cleavage di-
rected by a deoxyoligonucleotide speci¢c for the 5P-terminal U1
RNA (anti-U1, 5P-TTCAGGTAAGTACTCA-3P, lanes 2^4) or a pu-
tative single-stranded region of U3 RNA (anti-U3, 5P-
TGGTTTTCGGTGCTCT-3P, lanes 5^7). HeLa nuclear extract (45
Wg), RNasin (40 U; Roche), deoxyoligonucleotides (200 ng), RNase
H (1 U, Roche), Mg2 (3 mM) and transcription bu¡er (20 mM
HEPES, pH 7.9; 100 mM KCl; 0.2 mM EDTA; 0.5 mM DTT;
20% glycerol) in a volume of 15 Wl were pre-incubated at 30‡C for
45 min before the addition of RNA 9 (35, 70 and 105 pmol) to the
transcription reactions as described in Fig. 1A. Lane 1, control
without RNA depletion and inhibitor; lanes 8^10, without RNA de-
pletion.
Fig. 3. Inhibition of transcription initiation by RNA ligands. A:
Pre- and post-initiation inhibition of in vitro transcription from the
CMV promoter by RNA 9. For analysis of the post-initiation inhi-
bition, the globin DNA template and HeLa nuclear extract were
pre-incubated at 30‡C for 30 min. Then increasing amounts of
RNA 9 (35, 70 and 105 pmol) were added to the mixture which
was incubated at 30‡C for another 30 min. Transcription was
started by adding rNTPs and 32P-GTP, and total RNA was col-
lected 45 min after transcription initiation and analyzed as in Fig.
1A. The experimental procedure for pre-initiation inhibition was as
described in Fig. 1A except that HeLa nuclear extract was pre-incu-
bated before and after the addition of RNA 9, in parallel with sam-
ples for post-initiation inhibition. B: Inhibition of pol II binding to
the pre-initiation complex by RNA ligands. The transcription pre-
initiation complex was assembled on the immobilized CMV pro-
moter DNA (CMV/DNA) in the presence (+HeLa NE) or absence
(3HeLa NE) of HeLa nuclear proteins (45 Wg) and RNA competi-
tors (tRNA, RNA 5 and 9, 105 pmol each). Promoter bound pro-
teins were analyzed by Western blotting with anti-pol II antibody
(N-20). C: Model of RNA ligands-mediated inhibition of pol II
transcription.
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moter. As shown in Fig. 3A, RNA 9 e¡ectively impeded pol II
transcription when the ligand was added to the reactions prior
to transcription initiation. However, once the pre-initiation
complex was assembled on the promoter, RNA 9 was no
longer e¡ective. To investigate whether RNA 9 had a¡ected
pre-initiation complex assembly, a ligand^promoter competi-
tion experiment was performed. As shown in Fig. 3B, the
binding of pol II to the CMV promoter was inhibited by
RNA 9, while RNA 5 did not signi¢cantly a¡ect pol II bind-
ing to the CMV promoter as compared to non-speci¢c RNA
competitors such as tRNA. These results indicate that RNA 9
did not adversely a¡ect pol II activity, but speci¢cally inhib-
ited transcription initiation by blocking the recruitment of pol
II to the promoter.
This study shows that U1 snRNP and pol II appear to be
complexed before transcription initiation and through the
early stage of RNA splicing, and that U1 snRNP may play
an important role in co-ordinating transcription and RNA
splicing. This notion is also supported by the observations
that over-expression of a U1-speci¢c protein subunit represses
transactivation of pol II [27] and that pol II with a phosphor-
ylated carboxyl-terminal domain (CTD) stimulates RNA
splicing [14]. A recent study has also shown that a yeast
U1-speci¢c protein directly interacts with the phosphorylated
CTD of pol II in the early spliceosome [28]. These observa-
tions strengthen the model that the CTD of pol II provides a
‘platform’ on which snRNPs and other splicing factors assem-
ble to form the early spliceosome during transcription. Pol II
appears to undergo an activation process (e.g. through de-
phosphorylation and phosphorylation) to initiate transcrip-
tion [29]. In the present study, the activation of pol II for
transcription initiation may be abolished by the binding of
excessive nascent transcripts containing 5P-splice site (e.g.
RNA 9 and other ligands) to the pol II-associated U1
snRNP. Such association may render the transcription machi-
nery as a pseudo ‘elongation complex’ even when it is not
engaged with DNA, and therefore prevent the activation of
pol II for transcription initiation (Fig. 3C). Unlike putative
transcription factors, the interactions of U1 snRNP and other
RNA processing factors with the transcription machinery
most likely serve to link the events of transcription and
RNA processing, rather than to speci¢cally activate or repress
pol II activity in a promoter-dependent fashion. Therefore,
these processing factors should be regarded as ‘transcription
co-ordinators’. The current study demonstrates that RNA li-
gands selected for various gene products present in crude
cellular extracts may be utilized to identify novel functions
of speci¢c factors involved in complex molecular events. The
author anticipates that this RNA ligand-based strategy will
prove to be a valuable approach to the study of human pro-
teomes.
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